A study of Eli Lilly’s monoclonal antibody Ly-CoV555 in combination with Gilead Sciences’s Veklury (remdesivir) is the latest COVID-19 trial to be paused for safety concerns.
The US National Institute of Allergy and Infectious Disease’s ACTIV-3 trial is part of the agency’s master protocol for assessing...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
